What is Bitterroot Bio?
Bitterroot Bio is a biotechnology company dedicated to pioneering new immunotherapies targeting cardiovascular diseases. Operating from Palo Alto, the company leverages cutting-edge research to address unmet needs in a critical area of human health. Its focus on novel approaches positions it within the rapidly evolving landscape of biopharmaceutical innovation, aiming to translate scientific discovery into tangible patient benefits.
How much funding has Bitterroot Bio raised?
Bitterroot Bio has raised a total of $145M across 1 funding round:
Series A
$145M
Series A (2023): $145M with participation from Deerfield, ARCH VENTURE PARTNERS, and Alt Disrupt
Key Investors in Bitterroot Bio
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models and driving innovation using AI, data, and market research.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations.
Alt Disrupt
Koch Disruptive Technologies (KDT) empowers principled entrepreneurs by providing flexible capital solutions and access to a diverse ecosystem of experts and commercial partners, focusing on accelerating innovation and commercialization of transformative technologies.
What's next for Bitterroot Bio?
With this substantial enterprise-level backing and a recent strategic investment, Bitterroot Bio is poised for accelerated growth and development. The capital infusion is expected to fuel further research and development initiatives, potentially expanding clinical trials and enhancing the company's therapeutic offerings. This strategic financing suggests a strong market validation and provides the necessary resources for Bitterroot Bio to navigate the complex path from preclinical research to market-ready treatments in the competitive biotechnology sector.
See full Bitterroot Bio company page
